The National Institutes of Health (NIH) recently granted a $15.6 million award to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD), to support five years of research on mucolytic agents. The agents were discovered by the developmental stage biopharmaceutical company Parion Sciences,…
Two subsidiaries of Omnicare Specialty Care Group (SCG) recently announced they have been chosen to provide services to idiopathic pulmonary fibrosis (IPF) patients taking OFEV® (nintedanib), a recently-approved tyrosine kinase inhibitor developed by Boehringer Ingelheim. RxCrossroads and Advanced Care Scripts (ACS) have been selected to carry out reimbursement…
In a study entitled “Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis” published in BMC Pulmonary Medicine the authors report the first evidence of a relationship between ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis. Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare…
The companies Bristol-Myers Squibb and Galecto Biotech AB have signed an agreement giving Bristol the exclusive option to acquire Galecto, as well as the global rights for its lead products, an investigational inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic…
Promedior, Inc. recently announced in a press release that they have received FDA fast track designation for their compound – PRM-151 – as a promising, new therapeutic for patients with myelofibrosis. The new designation supports continuing evidence that PRM-151 may be a viable therapy for treating a range of diseases…
A novel study on the impact of supplemental oxygen prescription in pulmonary fibrosis entitled “Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis” was published in the journal BMC Pulmonary Medicine by Amanda Belkin, part of Dr. Jeffrey J Swigris’group from Autoimmune Lung Center and Interstitial Lung…
A new study entitled “Lung fibrotic tenascin-C up regulation is associated with other extracellular matrix proteins and induced by TGFβ1” and published in BMC Pulmonary Medicine journal suggests that the Tenascin C protein is a glycoprotein that may be relevant for fibroblastic foci activity and fibrosis…
A new study entitled “Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood” published in October issue of BMC Genomics reports that the diagnosis of sporadic idiopathic pulmonary fibrosis from peripheral blood samples by identifying a functional genetic signature.The new findings could have…
A broad perspective of idiopathic pulmonary fibrosis causes were recently discussed in a wide-ranging featured lecture published on AJMC entitled “Idiopathic Pulmonary Fibrosis: Biomarkers and New Treatment Options” by expert in idiopathic pulmonary fibrosis Steven K. Huang, MD at the 2014 American College of Chest…
Ofev (nintedanib) capsules, a new drug treatment for idiopathic pulmonary fibrosis (IPF) developed by Boehringer Ingelheim Pharmaceuticals, Inc. is already being made available in select pharmacies throughout the United States with a prescription. The announcement of Ofev’s availability was recently made by the company, and…
Get regular updates to your inbox.
